Vifor Pharma And Angion Sign License Agreement For Ang-3777 In Nephrology Indications

Vifor Pharma And Angion Biomedica Corp. (Angion) Announced The Signing Of A Licensing Agreement For The Commercialization Of Ang-3777, Currently Developed For Treatment Of Delayed Graft Function (Dgf) And Cardiac Surgery-Associated Acute Kidney Injury (Csa-Aki). Ang-3777 Was Engineered To Mimic The Biological Activity Of Hgf, Activating Critical Pathways In The Body&Rsquo;S Natural Organ Repair Process Following An Acute Organ Injury.Under The Terms Of The Agreement, Vifor Pharma Will Receive An Exclusive Global License, Excluding China, Taiwan, Hong Kong And Macau, For All Ang-3777 Nephrology Indications. Angion Will Receive Up To Usd 80 Million Which Includes A 30 Million Upfront Payment, A 30 Million Equity Investment And 20 Million In Clinical Study Milestone Payments. Additionally Angion Is Eligible To Receive Up To Usd 260 Million In Market Access Related Milestones Upon Approval In Us And Eu, Further Payments In The Form Of Sales Milestones, And Tiered Royalties On Global Net Sales Up To 40% At The High End Of The Royalty Range.&Ldquo;This Agreement Highlights The Leadership Position That Vifor Pharma Has Developed In The Nephrology Space And The Fact That It Has Become The Company Of Choice For Organizations Committed To Partnering Innovative Nephrology Focused Assets&Ldquo; Said Stefan Schulze, Chief Executive Officer Of Vifor Pharma. &Ldquo;Angion Is An Excellent Partner With An Outstanding Expertise Leading To The Development Of This Exciting Asset And Other Pipeline Products. We Look Forward To Working Closely With Angion Who Will Be Responsible For The Ongoing Development Program Of Ang-3777 And To Leveraging Our Commercial Expertise To Bring This Highly Promising, Innovative Treatment With A Unique Mode Of Action To Patients Suffering From Dgf And Csa-Aki. These Are Both Critical Conditions, Currently Without Any Effective Or Approved Therapies.&Rdquo;&Ldquo;Vifor Pharma Is One Of The World Leaders In The Nephrology Space And We Are Very Excited To Partner With Them On The Commercialization Of Ang

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!